{"id":"NCT05686044","sponsor":"Annovis Bio Inc.","briefTitle":"A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study of Buntanetap in Participants With Mild to Moderate Alzheimer's Disease","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2023-04-01","primaryCompletion":"2024-02-13","completion":"2024-02-13","firstPosted":"2023-01-17","resultsPosted":"2025-04-29","lastUpdate":"2025-04-29"},"enrollment":351,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Alzheimer Disease"],"interventions":[{"type":"DRUG","name":"Buntanetap/Posiphen","otherNames":["Posiphen Tartrate"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"7.5mg Buntanetap/Posiphen","type":"EXPERIMENTAL"},{"label":"15mg Buntanetap/Posiphen","type":"EXPERIMENTAL"},{"label":"30mg Buntanetap/Posiphen","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to measure efficacy and safety of three different doses of buntanetap/Posiphen compared with placebo in participants with mild to moderate Alzheimer's disease.\n\nStudy details include:\n\nThe double-blind treatment duration will include a screening period of up to 42 days followed by 12 weeks of treatment at home.\n\nThe study duration will be 4-5 months. There will be 4 in-clinic visits and 1 phone call.","primaryOutcome":{"measure":"Change From Baseline to Week 12 in ADAS-Cog11","timeFrame":"Baseline to the end of treatment period (12 weeks)","effectByArm":[{"arm":"Placebo","deltaMin":-2.32,"sd":0.533},{"arm":"7.5mg Buntanetap/Posiphen","deltaMin":-1.34,"sd":0.526},{"arm":"15mg Buntanetap/Posiphen","deltaMin":-3.01,"sd":0.534},{"arm":"30mg Buntanetap/Posiphen","deltaMin":-2.24,"sd":0.531}],"pValues":[]},"eligibility":{"minAge":"55 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":54,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":88},"commonTop":["Dizziness"]}}